Evaluating CT features in ovarian cancer for AI model development

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess whether computed tomography (CT) features at diagnosis in women with high-grade serous ovarian cancer (HGSOC) can be utilized to create an artificial intelligence model. The model will focus on identifying pathological involvement of the mesentery, which may affect the feasibility of optimal debulking surgery and predict resistance to platinum-based chemotherapy. The study will include women over 18 years old with confirmed HGSOC and mesenteric involvement, specifically those at advanced FIGO stages IIIB-IV.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Women with confirmed HGSOC wiht mesenteric involvment
2. Age \> 18 years
3. FIGO STAGE IIIB-IV
4. Primary diagnosis
5. Signed informed consent

Exclusion Criteria:

1. Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer)
2. Early stage disease (I and II stage)
3. CT scan not available
4. Non-primary diagnosis or patient subjected to neoadjuvant chemotherapy

Where it's running

• Advanced Radiology Center
  Roma, Italy Recruiting

Study contacts

• Principal investigator: Camilla Panico, Dr — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Camilla Panico, Dr
• Email: camilla.panico@policlinicogemelli.it
• Phone: +390630155701

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

• INSPIRE: Putting patient-reported info into multidisciplinary tumor boards

  This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama and 2 other locations · NCT07671937

• Ipalotinib and Sunitinib with Olaparib before surgery for HRD-positive advanced ovarian cancer

  This trial tests a neoadjuvant therapy combo in HRD-positive advanced ovarian cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 Anhui Provincial Cancer Hospital · Hefei · NCT07667751

• Avoiding a stoma after rectosigmoid surgery for advanced ovarian cancer

  This trial tests whether avoiding a protective stoma after rectosigmoid resection is safe for people undergoing cytoreductive surgery for advanced ovarian cancer.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07213193

• Short videos about genetic testing for ovarian and endometrial cancer patients

  This pilot will see if watching short English or Spanish videos helps patients with ovarian or endometrial cancer get genetic testing and referrals.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07084168

• Assessing whole-body metabolism in ovarian cancer patients

  This study is testing how ovarian cancer affects fat metabolism in women before, during, and after their treatment to see if it can help find new ways to treat the disease.

  Recruiting University of Tennessee Graduate School of Medicine · Knoxville, Tennessee · NCT06800105

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.